Loading...
Market
Which country will approve PBGENE-HBV trial next by end of 2025?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Official announcements from Precision BioSciences or relevant health authorities
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
United Kingdom • 25%
Other • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
USA • 25%
UK • 25%
Germany • 25%
Other • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
United States • 25%
Canada • 25%
Germany • 25%
Other • 25%